Dynamic blood pressure control and middle cerebral artery mean blood velocity variability at rest and during exercise in humans.
OBJECTIVE
Cardiac failure and ischaemic heart disease patients receive standard of care cardiac beta(1)-adrenergic blockade medication. Such medication reduces cardiac output and cerebral blood flow. It is unknown whether the beta(1)-adrenergic blockade-induced reduction of cardiac output in the presence of an exercise-induced reduction in cardiac-arterial baroreflex gain affects cerebral blood flow variability. This study evaluated the influence of cardiac output variability on beat-to-beat middle cerebral artery mean blood velocity (MCA V(mean)) during exercise with and without cardiac beta(1)-adrenergic blockade.


METHODS
Eight men (22 +/- 1 years; mean +/- SE) performed 15 min bouts of moderate (105 +/- 11 W) and heavy (162 +/- 8 W) intensity cycling before and after cardio-selective beta(1)-adrenergic blockade (0.15 mg kg(-1) metoprolol). The relationship between changes in cardiac output or mean arterial pressure (MAP) and MCA V(mean) as well as cardiac-arterial baroreflex gain were evaluated using transfer function analysis.


RESULTS
Both exercise intensities decreased the low frequency (LF) transfer function gain between cardiac output and MCA V(mean) (P < 0.05) with no significant influence of beta(1)-blockade. In contrast, the LF transfer function gain between MAP and MCA V(mean) remained stable also with no significant influence of metoprolol (P > 0.05). The LF transfer function gain between MAP and HR, an index of cardiac-arterial baroreflex gain, decreased from rest to heavy exercise with and without beta(1)-blockade (P < 0.05).


CONCLUSIONS
These findings suggest that the exercise intensity related reduction in cardiac-arterial baroreflex function at its operating point does not influence the dynamic control of MCA V(mean), even when the ability of exercise-induced increase in cardiac output is reduced by cardiac beta(1)-adrenergic blockade.
Ogoh
S
S
Department of Integrative Physiology, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. sogoh@hsc.unt.edu
Dalsgaard
M K
MK
Secher
N H
NH
Raven
P B
PB
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000704:Analysis of Variance; D017704:Baroreflex; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology*; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test / Q000379:methods; D006706:Homeostasis; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000494:pharmacology; D020768:Middle Cerebral Artery; D010807:Physical Endurance / Q000502:physiology; D012815:Signal Processing, Computer-Assisted; D017585:Ultrasonography, Doppler, Transcranial
D000319:Adrenergic beta-Antagonists; D008790:Metoprolol